Which therapy is primarily aimed at managing chronic inflammation in asthma patients?

Inhaled corticosteroids are the primary therapy aimed at managing chronic inflammation in asthma patients because they work by reducing airway inflammation, which is a hallmark of asthma. These medications act directly on the airways to decrease the production of inflammatory mediators and inhibit the activity of inflammatory cells, resulting in improved airflow and reduced symptoms over time.

Inhaled corticosteroids are the cornerstone of asthma management, particularly for patients with persistent symptoms, as they help control chronic inflammation and prevent exacerbations. Regular use helps in maintaining control of asthma by modifying the underlying pathophysiology, rather than just relieving acute symptoms.

The other therapies listed serve different roles in asthma management. Short-acting beta-agonists primarily provide quick relief from acute asthma symptoms and act as bronchodilators, but do not address inflammation. Long-acting beta-agonists also function as bronchodilators but are typically used in conjunction with inhaled corticosteroids and do not have direct anti-inflammatory effects. Leukotriene modifiers can be helpful in managing asthma and have some anti-inflammatory properties, but they are generally considered a second-line option compared to inhaled corticosteroids, particularly in cases of significant inflammation.